Compare Eli Lilly And Co (LLY) vs Banco Santander SA (SAN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Banco Santander SA — how do they compare? Eli Lilly And Co trades at $1,179.27 (market cap $1.04T), while Banco Santander SA trades at $13.49 (market cap $192.86B). The key difference: Eli Lilly And Co is far larger — about 5.4× Banco Santander SA's market cap, and Banco Santander SA pays the higher dividend (2.06%). Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Banco Santander SA for 55 Days on average.
| LLY | SAN | |
|---|---|---|
Market Cap | $1.04T | $192.86B |
Volume | 3,064,878 | 10,644,519 |
Sector | Health | Financials |
52-Week High | $1.28K | $15.05 |
52-Week Low | $799.57 | $9.65 |
Typical Hold Time | 93 Days | 55 Days |
Enterprise Value | $1.09T | $360.86B |
Dividend Yield | 0.59% | 2.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company demonstrates exceptional profitability with 83.4% gross margins and 33.53% net income margins, supported by dominant positioning in weight-loss and diabetes treatments. Recent clinical trial successes for next-generation drugs and expanded FDA approvals reinforce growth prospects.
LLY presents compelling growth potential with analyst consensus target of $1,350 representing 15% upside, though elevated valuations (P/E 39.26) and increasing competition in obesity drugs pose risks. Strong institutional support (73% buy ratings) and positive pipeline developments support continued momentum, but investors should monitor execution risks and market saturation concerns.
Banco Santander (SAN) trades at $13.48, down 1.32% on the day, amid a bearish technical signal. The stock shows mixed earnings performance, with a Q1 2026 beat but a Q2 2026 miss. Fundamentals are solid with a 26.25% net income margin and a P/E of 13.55, while cash flow trends have weakened significantly. Recent news highlights the completion of the Webster acquisition, expanding U.S. presence.
The outlook is cautiously optimistic given strong profitability and analyst support, but risks include declining cash flows, high debt levels, and economic sensitivity. The stock's current valuation may appeal to value-oriented investors, though near-term volatility is likely.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Banco Santander SA
Santander's focus is on retail and commercial banking. Latin America is geographically the largest operation, with Brazil by far the largest. Its continental European business is still mainly Iberian. Santander's U.K. presence is the result of the acquisition of building society Abbey. In the U.S., Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.
Read more on SAN →
